MY129677A - Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists - Google Patents

Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists

Info

Publication number
MY129677A
MY129677A MYPI20014364A MYPI20014364A MY129677A MY 129677 A MY129677 A MY 129677A MY PI20014364 A MYPI20014364 A MY PI20014364A MY PI20014364 A MYPI20014364 A MY PI20014364A MY 129677 A MY129677 A MY 129677A
Authority
MY
Malaysia
Prior art keywords
agonists
antagonists
substituted imidazoles
dual
dual histamine
Prior art date
Application number
MYPI20014364A
Other languages
English (en)
Inventor
Robert G Aslanian
Stuart B Rosenblum
Mutahi Mwangi Wa
Shih Neng-Yang
John J Piwinski
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MY129677A publication Critical patent/MY129677A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
MYPI20014364A 2000-09-20 2001-09-18 Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists MY129677A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23404000P 2000-09-20 2000-09-20

Publications (1)

Publication Number Publication Date
MY129677A true MY129677A (en) 2007-04-30

Family

ID=22879630

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20014364A MY129677A (en) 2000-09-20 2001-09-18 Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists

Country Status (14)

Country Link
US (1) US6518287B2 (enExample)
EP (1) EP1318983B1 (enExample)
JP (1) JP2004509870A (enExample)
CN (1) CN1461299A (enExample)
AR (1) AR032895A1 (enExample)
AT (1) ATE411983T1 (enExample)
AU (1) AU2001292723A1 (enExample)
CA (1) CA2421823A1 (enExample)
DE (1) DE60136284D1 (enExample)
ES (1) ES2313985T3 (enExample)
HK (1) HK1052181A1 (enExample)
MX (1) MXPA03002447A (enExample)
MY (1) MY129677A (enExample)
WO (1) WO2002024658A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050090527A1 (en) * 2003-01-28 2005-04-28 Schering Corporation Combination of H1, H3 and H4 receptor antagonists for treatment of allergic and non-allergic pulmonary inflammation, congestion and allergic rhinitis
BRPI0514857A (pt) * 2004-09-03 2008-05-06 Celgene Corp composto ou um sal, solvato ou hidrato farmaceuticamente aceitável do mesmo, composição farmacêutica, e, métodos para inibir a angiogênese, para inibir ou reduzir a polimerização da tubulina ou a estabilidade da tubulina em uma célula, para inibir a atividade de pde4 em uma célula, para inibir atividade do fator-alfa de necrose de tumor (tnf-alfa) em uma célula, para tratar ou melhorar um distúrbio inflamatório, para tratar ou melhorar cáncer, para inibir a proliferação de célula cancerosa, para marcar, bloquear ou destruir a função de vasculatura tumoral, para marcar, bloquear ou destruir o endotélio de vasos tumor, para marcar, bloquear ou destruir a função de vasculatura tumoral e inibir a angiogênese em um tumor e para tratar ou melhorar um distúrbio do sistema nervoso central
JP2009522246A (ja) * 2005-12-30 2009-06-11 ランバクシー ラボラトリーズ リミテッド ムスカリン性レセプターアンタゴニスト
EP2094643B1 (en) 2006-12-01 2012-02-29 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3512084A1 (de) * 1985-04-02 1986-10-09 Ludwig Heumann & Co GmbH, 8500 Nürnberg Guanidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
FR2586562B1 (fr) 1985-09-02 1989-03-10 Inst Nat Sante Rech Med Composition pharmaceutique contenant de l'a-methylhistamine
DE3631334A1 (de) * 1986-09-15 1988-03-17 Heumann Pharma Gmbh & Co Neue imidazolylguanidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB8916947D0 (en) 1989-07-25 1989-09-13 Smith Kline French Lab Medicaments
DK0448765T3 (da) 1990-03-30 1994-09-19 Heumann Pharma Gmbh & Co Anvendelse af guanidinderivater til fremstilling af et lægemiddel med NPY-antagonistisk virkning
GB9115740D0 (en) 1991-07-20 1991-09-04 Smithkline Beecham Plc Medicaments
CA2125964C (en) 1991-12-18 2001-06-19 Neng-Yang Shih Imidazolyl-alkyl-piperazine and -diazepine derivatives as histamine h3 agonists/antagonists
FR2686084B1 (fr) * 1992-01-10 1995-12-22 Bioprojet Soc Civ Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
US5352707A (en) 1992-03-26 1994-10-04 Harbor Branch Oceanographic Institution, Inc. Method for treating airway congestion
HUT74386A (en) 1993-11-15 1996-12-30 Schering Corp Phenyl-alkyl imidazoles as h3-receptor antagonists and pharmaceutical compositions containing them
FR2732017B1 (fr) 1995-03-21 2000-09-22 Inst Nat Sante Rech Med Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques
DK1019050T3 (da) 1997-06-24 2002-07-08 Novo Nordisk As Anvendelse af somatostatinagonister og -antagonister til behandling af sygdomme i forbindelse med øjet
US5869479A (en) 1997-08-14 1999-02-09 Schering Corporation Treatment of upper airway allergic responses
US6211182B1 (en) * 1999-03-08 2001-04-03 Schering Corporation Imidazole compounds substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms

Also Published As

Publication number Publication date
HK1052181A1 (zh) 2003-09-05
ES2313985T3 (es) 2009-03-16
EP1318983A2 (en) 2003-06-18
AR032895A1 (es) 2003-12-03
US6518287B2 (en) 2003-02-11
CN1461299A (zh) 2003-12-10
AU2001292723A1 (en) 2002-04-02
US20020103235A1 (en) 2002-08-01
DE60136284D1 (de) 2008-12-04
EP1318983B1 (en) 2008-10-22
WO2002024658A3 (en) 2002-07-11
MXPA03002447A (es) 2003-07-21
ATE411983T1 (de) 2008-11-15
WO2002024658A2 (en) 2002-03-28
CA2421823A1 (en) 2002-03-28
JP2004509870A (ja) 2004-04-02

Similar Documents

Publication Publication Date Title
MXPA02005602A (es) Compuestos de urea que tienen actividad antagonista para el receptor muscarinico.
TR200201568T2 (tr) İkame edilmiş imidazol nöropeptid Y Y5 reseptörü antagonistleri.
MXPA02005596A (es) Derivados de carbamato con actividad antagonista para el rerceptor muscarinico.
WO2004087649A3 (en) Benodiazepine spirohydantoin cgrp receptor antagonists
MXPA04000707A (es) Nuevos antagonistas del receptor y5 del neuropeptido y referencia cruzada a solicitudes relacionadas.
WO2003028650A3 (en) Benzimidazolidinone derivatives as muscarinic agents
CR9304A (es) Antagonistas del receptor de glucagon, preparaciones y usos terapeuticos
PL363907A1 (en) Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain.
JO2355B1 (en) Hereditary calcitonin polypeptide receptor antagonists
MY161834A (en) Substituted diazepan compounds as orexin receptor antagonists
TW200510429A (en) Heterocyclic MCHR1 antagonists
WO2001071022A3 (en) Lpa receptor agonists and antagonists and methods of use
DK1377586T3 (da) Tricykliske diazepiner som tocolytiske oxytocinreceptorantagonister
UA86621C2 (ru) Антагонисты рецептора глюкагона, их получение и терапевтическое применение
WO2005060959A8 (en) Pyrazole derivatives and use thereof as orexin receptor antagonists
EP1398029A8 (en) NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives
AU1092800A (en) N-(imidazolylalkyl)substituted cyclic amines as histamine-H3 agonists or antagonists
AU2003274307A1 (en) 5-ht 1b/1d receptor agonists for the treatment of headache resulting from administering an endothelin receptor antagonist
WO2005082893A3 (en) Histamine h3 receptor antagonists, preparation and therapeutic uses
WO2002044141A3 (en) Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
MY117975A (en) Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
TW200726764A (en) N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
PT1673354E (pt) Arilindenopiridinas e arilindenopirimidinas e sua utilização como antagonistas do receptor da adenosina a2a
MY129677A (en) Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
WO2004026837A3 (en) Histamine h3 receptor antagonists, preparaton and therapeutic uses